Literature DB >> 34115456

Trifecta achievement in patients undergoing partial nephrectomy: a systematic review and meta-analysis of predictive factors.

Nigemutu Bai1, Muge Qi2, Dan Shan3, Suo Liu1, Ta Na1, Liang Chen1.   

Abstract

PURPOSE: The predictors of trifecta achievement in partial nephrectomy (PN) were poorly inquired and remained a controversial area of discovery. To evaluate predictive factors of trifecta achievement in patients undergoing PN.
MATERIALS AND METHODS: A systematic literature search was performed to identify relevant articles. Only studies focusing on postoperative trifecta achievement and exploring its predictor with multivariable analyses were included. The trifecta achievement was defined as negative surgical margins, warm ischemia time <25 minutes, and no complications. Merged odds ratio (OR) and 95% confidence interval (CI) were used to evaluate the predictive effect.
RESULTS: Thirteen studies with 7066 patients meeting the inclusion criteria were included. The rate of trifecta achievement ranged from 43.3% to 78.6%. Merged results showed that preoperative eGFR (OR: 1.01, 95% CI: 1.00, 1.02, P=0.02), operative time (OR: 0.99, 95% CI: 0.99, 1.00, P=0.02), estimated blood loss (OR: 1.00, 95% CI: 1.00, 1.00, P <0.001), tumor size (OR: 0.70, 95% CI: 0.58, 0.84, P <0.001), medium (OR: 0.39, 95% CI: 0.18, 0.84, P=0.02) and high PADUA score (OR: 0.23, 95% CI: 0.08, 0.64, P=0.005) were independently associated with trifecta achievement. A publication bias was identified for tumor size. Sensitivity analysis confirmed the stability of result for tumor size.
CONCLUSIONS: Larger tumor size, medium and high PADUA score are associated with decreased probability of trifecta achievement. After verifying by further high-quality studies, these variables can be incorporated into tools to predict probability of trifecta achievement during clinical practice. Copyright® by the International Brazilian Journal of Urology.

Entities:  

Keywords:  Kidney Neoplasms ; Nephrectomy; Systematic Review [Publication Type]

Mesh:

Year:  2022        PMID: 34115456      PMCID: PMC9306373          DOI: 10.1590/S1677-5538.IBJU.2021.0095

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   3.050


INTRODUCTION

In 2020, kidney and renal pelvis cancer was estimated to be associated with nearly 73.750 newly diagnosed patients and 14.830 cancer-related deaths in the United States ( 1 ). Renal cell carcinoma accounts for the vast majority of these cases. Compared with radical nephrectomy, partial nephrectomy (PN) is more effective for cT1a renal masses in terms of surgically related mortality, overall survival, and renal function, and has become a standard treatment regimen ( 2 , 3 ). In addition, for larger renal masses (cT1b and cT2), a recent study has shown that PN can offer the same cancer control, better preserved renal function, acceptable surgical morbidity, and potential better long-term survival compared to radical surgery ( 4 ). With the development of medical instruments, PN has evolved from open surgery to laparoscopic and robot-assisted surgery, and became widely applied in managing highly complex kidney cancer ( 5 , 6 ). As a novel concept from radical prostatectomy, the trifecta outcome was initially proposed by Hung et al. to describe the outcome of partial nephrectomy ( 7 ). It provides a definition of an ideal surgical outcome that includes the following three criteria: negative surgical margins, maximum renal function retention and patient recovery without complications. The use of trifecta rate as a key indicator of partial nephrectomy success has been widely reported ( 8 - 11 ). Recently, some researchers have proposed several anatomic classification scoring systems to classify and stratify patients into different anatomic complexity groups, and allow doctors to evaluate perioperative outcomes ( 12 - 15 ). In addition to these anatomic scoring systems, some other perioperative variables such as age, gender, BMI, tumor size, operative time, estimated blood loss have been studied as predictive factors for trifecta achievement in patients undergoing partial nephrectomy ( 16 - 20 ). However, inconsistent results reported by different studies confuse our understanding and interpretation. Hence, based on studies reporting predictive factors for trifecta achievement, we merged the results using the method of systematic review and meta-analysis.

MATERIALS AND METHODS

The protocol of the present study was registered on PROSPERO (ID: CRD42020220307). The PRISMA checklist was presented in supplementary data.

Literature researching

After establishing a prior study protocol, two authors independently used PubMed, Embase and Cochrane Library, respectively, to conduct a literature search for post-PN trifecta achievement until September 2020. The free-text strategy was considered best suited to this purpose: “post-PN trifecta achievement”. The key words included “partial nephrectomy”, “nephron sparing surgery”, “trifecta”, “trifecta achievement”. The language was restricted to English, non-English articles were filtrated. Publication type was restricted to original article, reviews, congress abstracts, letters to editor, editorials, erratum, and short communications were filtrated.

Study selection

The studies focused on patients with renal tumor who had undergone partial nephrectomy and achieved trifecta or not. The trifecta achievement was defined as negative surgical margins, warm ischemia time <25 minutes, and no complications. Predictive factors of post-PN trifecta achievement were studied with multivariable logistic analyses and reported in included studies. The abstract of each study was evaluated to assess the eligibility of the study. Those studies that provided relevant data were chosen for detailed checking. The studies were excluded due to the following reasons: ( 1 ) didn’t reported relevant outcomes, ( 2 ) without results from multivariable analysis, ( 3 ) inconsistent definition of trifecta achievement, ( 4 ) duplicated publication.

Data extraction

Based on the included studies, the following data were extracted: ( 1 ) study features (first author’s name, publication year, study design, patient resource, study period, country, sample size); ( 2 ) patient characteristics (age, surgical procedure, T stage, rate of trifecta, variables included in multivariable analysis); ( 3 ) predictors of trifecta achievement (multivariable odds ratio [OR] and 95% confidence interval [CI] of age, body mass index (BMI), Charlson comorbidity index, preoperative estimated glomerular filtration rate (eGFR), operative time, estimated blood loss, tumor size, N score component, RENAL score, PADUA score (medium or high vs. low)).

Study quality assessment

For non-randomized controlled studies, the Newcastle-Ottawa Assessment Scale was considered appropriate for the assessment of study quality ( 21 ) and established a value ladder, with a score of 5 for low-quality studies, 6-7 for medium-quality studies, and 8-9 for high-quality studies.

Data analysis

Multivariable ORs and 95% CIs from each study were merged to assess the predictive effect of factors for post-PN trifecta achievement. Only the factors reported by more than two studies were included in the meta-analyses. The Cochrane Q p value and I2 statistic were used to determine the heterogeneity between reports. This was deemed to be significant when p <0.05 or I2> was 50%, and a random-effect model was used to combine the results. Or else, a fixed-effect model was used. To assess publication bias (only for comparisons that include most studies), we examined funnel plots and performed sensitivity analyses of these comparisons. P <0.05 was considered statistically significant. All statistical analyses were conducted using Review Manager 5.3 (Cochrane Collaboration, Oxford, UK) and Stata 12.0 software (StatCorp, College Station, TX, USA).

RESULTS

Included studies

According to the flowchart of literature searching ( Figure-1 ), 44 studies were selected for detailed evaluation. Of them, 10 were excluded due to not reporting outcomes, 20 describing inconsistent definitions of trifecta were excluded, and 1 was a duplicate publication. Finally, 13 studies meeting the inclusion criteria were included ( 16 - 20 , 22 - 29 ).
Figure 1

Flow diagram detailing the search strategy and identification of studies included in data synthesis.

Baseline characteristics of studies

Eight studies relied on data from multi-institutional database, five studies analyzed patients in single center. Two studies prospectively collected data, and the rest studied retrospectively collected data. In terms of country, 3 were from Japan, 3 from Italy, 2 from France, 2 from Germany, 2 from USA, 1 from Korea. The median sample size was 285 (60-2392). The median or mean age ranged from 49.5 to 63.2 years. Most PN were performed in minimally invasive approach (laparoscopic or robot-assisted). The rate of trifecta achievement ranged from 43.3% to 78.6% ( Table-1A ). The detailed variables in multivariable analysis are presented in Table-2 , most of them were patients features, tumor characteristics, and surgical variables. Six were medium-quality (score 6-7) studies, seven were high-quality (score 8) studies, the detailed risk of bias for each study is presented in supplementary Table-S1 . The other characteristics and perioperative outcomes are detailed in supplementary Table-1B .
Table 1A

Baseline characteristics of included studies.

First authorYearDesignPatient populationStudy periodCountrySample sizeAge (years)ProcedureT stageTrifecta (%)
Furukawa et al. ( 22 )2020RetroMulti-institution2011-2016Japan80463 (55-70)RAPNpT1a-T3a62.1
Takeda et al. ( 23 )2020RetroSingle institution2006-2016Japan6654.5 MeanLPNcT1a55
Peyronnet et al. ( 16 )2018RetroMulti-institution2009-2015France109960.3 MeanRAPN-75.2
Khene et al. ( 17 )2018RetroMulti-institution2010-2016France50059 (51-67)RAPNpT1-T3a70.4
Harke et al. ( 18 )2018RetroMulti-institution2008-2016Germany140-OPN/RAPN-OPN: 68.4; RAPN: 75.0
Castellucci et al. ( 19 )2018RetroSingle institution2013-2016Italy12363.2±13.6RAPN-64.2
Paulucci et al. ( 24 )2017RetroMulti-institution2008-2016USA96061 (51-69)RAPN-72.2
Lebentrau et al. ( 25 )2017RetroSingle institution2006-2013Germany124-OPNcT169.4
Porpiglia et al. ( 26 )2016ProMulti-institution2009-2012Italy28560.3±14.3OPN/LPN/RAPNcT1bOPN: 62.4; LPN: 63.2; RAPN: 69.5
Kim et al. ( 27 )2016RetroSingle institution2006-2015Korea6049.5 (39.8-62)RAPNcT1b43.3
Zargar et al. ( 20 )2015RetroMulti-institution2004-2013USA1831-LPN/RAPNcT1aLPN: 33.0; RAPN: 70.0
Osaka et al. ( 28 )2015RetroSingle institution2007-2012Japan6357.9±10.2LPNcT1a61.9
Minervini et al. ( 29 )2014ProMulti-institution2009-2011Italy45062.7 MeanOPN/LPNcT1aOPN: 78.6; LPN: 74.3

Retro = retrospective; Pro = prospective; RAPN = robot-assisted partial nephrectomy; LPN = laparoscopic partial nephrectomy; OPN = open partial nephrectomy.

Table 2

Included variables in multivariable analysis and study quality.

AuthorYearVariables included in multivariable analysisNOS score
Furukawa et al. ( 22 )2020tumor size, OT, EBL, RENAL score, N score component, hilar location8
Takeda et al. ( 23 )2020tumor size6
Peyronnet et al. ( 16 )2018tumor size, RENAL score, surgeon experience, surgeon volume, hospital volume8
Khene et al. ( 17 )2018age, CCI, ECOG, tumor size, RENAL score, MAP score8
Harke et al. ( 18 )2018age, BMI, CCI, tumor size, solitary kidney, PADUA score, OPN vs RAPN, experience8
Castellucci et al. ( 19 )2018age, symptoms, tumor size, PADUA score, preoperative eGFR, EBL, OT7
Paulucci et al. ( 24 )2017surgeon experience, tumor size7
Lebentrau et al. ( 25 )2017age, sex, BMI, eGFR, ASA, PADUA score, surgical experience7
Porpiglia et al. ( 26 )2016tumor growth pattern, EBL, centers8
Kim et al. ( 27 )2016tumor size, OT, EBL7
Zargar et al. ( 20 )2015RAPN vs LPN, tumor size, RENAL score, EBL, OT8
Osaka et al. ( 28 )2015preoperative eGFR, tumor size, nearness of UCS, Surgeon’s learning curve7
Minervini et al. ( 29 )2014age, tumor size, indication8

OT = operative time; EBL = estimated blood loss; CCI = charlson’s comorbidity index; ECOG = Eastern Cooperative Oncology Group; BMI = body mass index; OPN = open partial nephrectomy; RAPN = robot-assisted partial nephrectomy; eGFR = estimated glomerular filtration rate; ASA = American Society of Anesthesiologists; LPN = laparoscopic partial nephrectomy; UCS = urinary collecting system.

Table 1B

The other characteristics and perioperative outcomes for included studies.

First authorYearGender (male/female)Median BMI (kg/m2)Median tumor size (cm)Median nephrometry scoreTotal complication (n)Median OT (min)Median WIT (min)Median EBL (mL)Median LOS (d)PSM (n)
Furukawa et al. ( 22 )2020584/220-2.67 R132 (Clavien≥III: 74)234213098
Takeda et al. ( 23 )202055/11---8 (I: 0, II: 3, III: 5)----0
Peyronnet et al. ( 16 )2018712/387---162 (Clavien≥III: 60)----56
Khene et al. ( 17 )2018297/203273.37 R125 (Clavien≥III: 49)16015250319
Harke et al. ( 18 )201890/50--11 P30 (Clavien≥III: 16)----2
Castellucci et al. ( 19 )201870/5327--23 (II: 15, III: 7, IV:1)115-205-14
Paulucci et al. ( 24 )2017568/39229.337 R115 (Clavien≥III: 33)17916100138
Lebentrau et al. ( 25 )2017 --------8
Porpiglia et al. ( 26 )2016171/11425.95-31 (II: 17, III: 8)13516200-9
Kim et al. ( 27 )201633/2724.759 R9 (II: 7, III: 2, IV:0)165.5-425-4
Zargar et al. ( 20 )20151097/73430--359----100
Osaka et al. (89)201550/1324.7246 R41772187-4
Minervini et al. ( 29 )2014179/101-2.5-46-----

BMI = body mass index; OT = operative time; WIT = warm ischemia time; EBL = estimated blood loss; LOS = length of hospital stay; PSM = positive surgical margin; R = RENAL; P = PADUA.

Retro = retrospective; Pro = prospective; RAPN = robot-assisted partial nephrectomy; LPN = laparoscopic partial nephrectomy; OPN = open partial nephrectomy. BMI = body mass index; OT = operative time; WIT = warm ischemia time; EBL = estimated blood loss; LOS = length of hospital stay; PSM = positive surgical margin; R = RENAL; P = PADUA. OT = operative time; EBL = estimated blood loss; CCI = charlson’s comorbidity index; ECOG = Eastern Cooperative Oncology Group; BMI = body mass index; OPN = open partial nephrectomy; RAPN = robot-assisted partial nephrectomy; eGFR = estimated glomerular filtration rate; ASA = American Society of Anesthesiologists; LPN = laparoscopic partial nephrectomy; UCS = urinary collecting system.

Predictors of trifecta achievement

Most predictive factors were patients features, surgical variables, and tumor characteristics. Patients features were analyzed as continuous variables. Since no significant heterogeneity was identified (I2=0%-12%, P=0.30-0.85), the fixed-effect model was used. A pooled analysis of ORs proved age (OR: 1.00, 95% CI: 0.98, 1.02, P=0.79), body mass index (OR: 0.96, 95% CI: 0.91, 1.02, P=0.17), Charlson comorbidity index (OR: 0.98, 95% CI: 0.84, 1.13, P=0.74) weren’t independent predictive factors for trifecta achievement ( Figures 2 A-C ). The merged results showed that preoperative eGFR (OR: 1.01, 95% CI: 1.00, 1.02, P=0.02) was independently associated with trifecta achievement, but the predictive effect was minor ( Figure-2D ).
Figure 2

Forest plots for predictors of trifecta achievement. The predictors included (A) age, (B) body mass index, (C) Charlson comorbidity index, (D) preoperative estimated glomerular filtration rate, (E) operative time, (F) estimated blood loss.

Since significant heterogeneity was identified (I2=74%, P=0.008), the random-effect model was used for operative time. Since no significant heterogeneity was identified (I2=42%, P=0.14), the fixed-effect model was used for estimated blood loss. A pooled analysis of ORs demonstrated operative time (OR: 0.99, 95% CI: 0.99, 1.00, P=0.02) and estimated blood loss (OR: 1.00, 95% CI: 1.00, 1.00, P <0.001) were independently associated with trifecta achievement, but the predictive effect was minor ( Figures 2E and F ). Tumor characteristics included tumor size, N score component, RENAL score, and PADUA score. Due to significant heterogeneity, the random-effect model was used for tumor size and RENAL score, the fixed-effect model was used for other meta-analyses. Pooled analysis of ORs demonstrated tumor size (OR: 0.70, 95% CI: 0.58, 0.84, P <0.001), medium (OR: 0.39, 95% CI: 0.18, 0.84, P=0.02) and high PADUA score (OR: 0.23, 95% CI: 0.08, 0.64, P=0.005) were independently associated with trifecta achievement ( Figures 3A , D and E ). N score component (OR: 0.83, 95% CI: 0.65, 1.05, P=0.12) and RENAL score (OR: 0.68, 95% CI: 0.35, 1.34, P=0.27) weren’t independent predictive factors for trifecta achievement ( Figures 3 B and C ).
Figure 3

Forest plots for predictors of trifecta achievement. The predictors included (A) tumor size, (B) N score component, (C) RENAL score, (D) PADUA score (medium vs. low), (E) PADUA score (high vs. low).

Bias assessment

Given the inadequate studies, publication bias checking and sensitivity analysis were only performed for tumor size. The funnel plot seemed to be asymmetric ( Figure-4A ), and Egger’s test identified significant difference (P=0.001). Sensitivity analysis confirmed the stability of results ( Figure-4 B).
Figure 4

(A) Funnel plot to assess publication bias for tumor size, (B) sensitivity analysis for tumor size.

DISCUSSION

A comprehensive outcome measure, the trifecta achievement (i.e., negative surgical margins, warm ischemia time <25 minutes, no complications), has been recommended as a measure of postoperative surgical quality for PN ( 24 , 26 , 28 , 29 ). Some perioperative parameters including patient features, tumor characteristics, and surgical variables were hypothesized to be associated with the trifecta achievement of PN. We firstly assessed the predictive factors of trifecta achievement for patients undergoing PN with the method of systematic review and meta-analysis. The present study included 7.066 patients, and the rate of trifecta achievement ranged from 43.3% to 78.6%. High variability was found regarding the rate of trifecta achievement may due to the differences in patient condition, tumor size and stage, surgical approach, and so on. More than thirty studies have reported predictive factors for trifecta achievement, however, different definitions of trifecta achievement were described. Trifecta achievement was consisted of three aspects, namely surgical margin, renal function preservation, and perioperative complication. The inconsistency lies mainly in the latter two aspects. The most common definition was adopted, specifically negative surgical margins, warm ischemia time <25 minutes, and no complications. Finally, 13 studies meeting the inclusion criteria were included ( 16 - 20 , 22 - 29 ). The detailed variables in multivariable analysis are presented in Table- 2, most of them were patients features, tumor characteristics, and surgical variables. For the same variables, different forms of data were used in different studies, and the most common data type was chosen. Based on the results from multivariable analyses, several independent predictors have been identified. Patients features including age, body mass index, Charlson comorbidity index, and preoperative eGFR were analyzed as continuous variables. Only preoperative eGFR was found to be independently associated with trifecta achievement. However, the predictive effect was minor, the odd ratio was 1.01 (1.00-1.02). Moreover, a recent study based on 790 patients treated with laparoscopic PN found that preoperative eGFR (OR: 1.01, 95% CI: 1.00, 1.02) was associated with an increased probability of pentafecta achievement ( 30 ). These results indicated that preoperative eGFR had a limited effect on postoperative outcomes. Surgical variables including operative time and estimated blood loss were analyzed as continuous variables. Though they were found to be independently associated with trifecta achievement, the predictive effect was minor, the odd ratios were 0.99 (0.99-1.00) and 1.00 (1.00-1.00). Moreover, these two variables were related to surgery, and only can be obtained after surgery, their predictive value was limited. Tumor characteristics including tumor size, N score component, RENAL score, and PADUA score were analyzed. The variable tumor size has been most studied and reported in the included literatures. Merged data showed that tumor size (OR: 0.70, 95% CI: 0.58, 0.84) was associated with a decreased probability of trifecta achievement. This result is reasonable because tumor size obviously affects the two components (renal function, perioperative complication) of trifecta achievement. Reynolds et al. ( 31 ) have compared perioperative and functional outcomes for patients with clinical T1a and T1b renal tumors undergoing robot-assisted PN. They found that clinical T1a tumors were correlated with shorter warm ischemia time, lower rate of perioperative complications. Similarly, in the setting of robot-assisted PN, Delto et al. ( 32 ) have compared perioperative outcomes for patients with clinical T1a, T1b, and T2a renal tumors. They found that clinical T2a renal tumors were associated with a 7% increase in warm ischemia time, a 3.93 higher odds of acute kidney injury compared to T1a renal tumors. Both the two studies didn’t identify significant difference in surgical margins among different clinical stage renal tumors. Due to the significant effect of tumor size on ischemia time and perioperative complication, Castellucci et al. ( 33 ) have reported that patients with renal masses ≥4cm achieved an obviously lower rate of trifecta achievement (44.7% vs. 72.9%) than those with renal masses <4cm. In terms of anatomic scoring systems, renal tumors with medium (OR: 0.39, 95% CI: 0.18, 0.84) and high PADUA score (OR: 0.23, 95% CI: 0.08, 0.64) were associated with decreased probability of trifecta achievement when compared with those with low PADUA score. These results seemed to be reasonable, more complex tumors may experience more unfavorable perioperative outcomes. However, no significant difference was identified for N score component and RENAL score. The possible reasons included limited studies have reported these results, and these two variables were analyzed in continuous variable which underestimate the differences. Though the present study stands for the first systematic review and meta-analysis about the predictive factors for trifecta achievement in patients undergoing partial nephrectomy, several limitations need to be addressed. First, all included studies were retrospectively designed or database based, and therefore inherent biases were included. Some studies were of moderate quality and cannot be comparable for each related variable. Hence, we just analyzed the results from multivariable analyses which adjusted the confounding factors. Second, more than thirty studies have reported predictive factors for trifecta achievement, however, different definitions of trifecta achievement were described. The most common definition was adopted, then 13 studies were included. Some endpoints were reported by limited studies and analyzed in different data type, the pooled results for theses endpoints should been verified by further studies. Moreover, due to the inadequate studies, some important variables such as surgical approach have not been analyzed in our study. Third, there were significant heterogeneity among studies for some endpoints, such as tumor size, operative time. The publication bias checking identified a potential publication bias for tumor size. Hence, these results might be interpreted with caution.

CONCLUSIONS

Trifecta achievement provides a definition of an ideal surgical outcome for patients undergoing partial nephrectomy. Larger tumor size, medium and high PADUA score are associated with decreased probability of trifecta achievement. After verifying by further high-quality studies, these variables can be incorporated into tools to predict probability of trifecta achievement during clinical practice.
  32 in total

1.  Which patients with clinical localized renal mass would achieve the trifecta after partial nephrectomy? The impact of surgical technique.

Authors:  Lorenzo Bianchi; Riccardo Schiavina; Marco Borghesi; Francesco Chessa; Carlo Casablanca; Andrea Angiolini; Amelio Ercolino; Cristian V Pultrone; Federico Mineo Bianchi; Umberto Barbaresi; Pietro Piazza; Fabio Manferrari; Alessandro Bertaccini; Michelangelo Fiorentino; Matteo Ferro; Angelo Porreca; Emanuela Marcelli; Eugenio Brunocilla
Journal:  Minerva Urol Nefrol       Date:  2019-10-10       Impact factor: 3.720

2.  Prediction of pentafecta achievement following laparoscopic partial nephrectomy: Implications for robot-assisted surgery candidates.

Authors:  Liangyou Gu; Kan Liu; Songliang Du; Hongzhao Li; Xin Ma; Qingbo Huang; Qing Ai; Wenzheng Chen; Yu Gao; Yang Fan; Yongpeng Xie; Yuanxin Yao; Hanfeng Wang; Pin Li; Yundong Xuan; Baojun Wang; Xu Zhang
Journal:  Surg Oncol       Date:  2020-01-07       Impact factor: 3.279

3.  Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery.

Authors:  Vincenzo Ficarra; Giacomo Novara; Silvia Secco; Veronica Macchi; Andrea Porzionato; Raffaele De Caro; Walter Artibani
Journal:  Eur Urol       Date:  2009-08-04       Impact factor: 20.096

4.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

5.  Trifecta Outcomes of Partial Nephrectomy in Patients Over 75 Years Old: Analysis of the REnal SURGery in Elderly (RESURGE) Group.

Authors:  Ahmet Bindayi; Riccardo Autorino; Umberto Capitanio; Nicola Pavan; Maria Carmen Mir; Alessandro Antonelli; Toshio Takagi; Riccardo Bertolo; Tobias Maurer; Koon Ho Rha; Jean Alexandre Long; Bo Yang; Luigi Schips; Estevão Lima; Alberto Breda; Estefania Linares; Antonio Celia; Cosimo De Nunzio; Ryan Dobbs; Sunil Patel; Zachary Hamilton; Andrew Tracey; Alessandro Larcher; Carlo Trombetta; Carlotta Palumbo; Kazunari Tanabe; Thomas Amiel; Ali Raheem; Gaelle Fiard; Chao Zhang; Roberto Castellucci; Joan Palou; Stephen Ryan; Simone Crivellaro; Francesco Montorsi; Francesco Porpiglia; Ithaar H Derweesh
Journal:  Eur Urol Focus       Date:  2019-02-22

6.  Robot-assisted partial nephrectomy for large renal masses: a multi-institutional series.

Authors:  Joan C Delto; David Paulucci; Michael W Helbig; Ketan K Badani; Daniel Eun; James Porter; Ronney Abaza; Ashok K Hemal; Akshay Bhandari
Journal:  BJU Int       Date:  2018-03-01       Impact factor: 5.588

7.  'Trifecta' outcomes of robot-assisted partial nephrectomy: a large Japanese multicenter study.

Authors:  Junya Furukawa; Hiroomi Kanayama; Haruhito Azuma; Keiji Inoue; Yasuyuki Kobayashi; Akira Kashiwagi; Takehiko Segawa; Yoshihito Takahashi; Shigeo Horie; Osamu Ogawa; Atsushi Takenaka; Ryoichi Shiroki; Kazunari Tanabe; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2019-11-01       Impact factor: 3.402

8.  Oncological and functional outcomes of open versus laparoscopic partial nephrectomy in T1b tumors: A single-center analysis.

Authors:  Ibrahim Kartal; Nihat Karakoyunlu; Çağlar Çakici; Osman Karabacak; Levent Sağnak; Hamit Ersoy
Journal:  Int Braz J Urol       Date:  2020 May-Jun       Impact factor: 1.541

9.  Newcastle-Ottawa Scale: comparing reviewers' to authors' assessments.

Authors:  Carson Ka-Lok Lo; Dominik Mertz; Mark Loeb
Journal:  BMC Med Res Methodol       Date:  2014-04-01       Impact factor: 4.615

10.  How far is too far? Exploring the indications for robotic partial nephrectomy in a highly complex kidney tumor.

Authors:  Andrea Minervini; Antonio Andrea Grosso; Fabrizio Di Maida; Andrea Mari; Gianni Vittori; Gianluca Muto; Marco Carini
Journal:  Int Braz J Urol       Date:  2020 Sep-Oct       Impact factor: 3.050

View more
  2 in total

1.  Vesical imaging reporting and data system (VI-RADS) in bladder cancer diagnosis in review in this number of International Brazilian Journal of Urology.

Authors:  Luciano A Favorito
Journal:  Int Braz J Urol       Date:  2022 Jul-Aug       Impact factor: 3.050

2.  Practical evaluation of the R.E.N.A.L. score system in 150 laparoscopic nephron sparing surgeries.

Authors:  Victor T Dubeux; José Fernando C Zanier; Pedro N Gabrich; Fabricio B Carrerette; José C A Milfont; Ronaldo Damião
Journal:  Int Braz J Urol       Date:  2022 Jan-Feb       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.